Perkins Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Perkins Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-20,000	Closed	-$193K	–	109
2020 Q4	$193K	Buy	+20,000	New	+$192K	0.13%	86
2018 Q1	–	Sell	-12,325	Closed	-$234K	–	126
2017 Q4	$234K	Buy	+12,325	New	+$185K	0.23%	92
2015 Q4	–	Sell	-5,300	Closed	-$299K	–	128
2015 Q3	$299K	Hold	5,300	–	–	0.33%	85
2015 Q2	$313K	Hold	5,300	–	–	0.27%	86
2015 Q1	$330K	Hold	5,300	–	–	0.28%	96
2014 Q4	$305K	Hold	5,300	–	–	0.26%	95
2014 Q3	$285K	Hold	5,300	–	–	0.24%	99
2014 Q2	$278K	Buy	+5,300	New	+$271K	0.2%	104

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Perkins Capital Management's TEVA Position: Q1 2021 in Review

Perkins Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2021, closing a stake of 20,000 shares — an estimated $193K sold.

Perkins Capital Management first reported a position in TEVA in Q2 2014 and held it in 8 quarters. The position peaked at $330K in Q1 2015. 451 funds tracked by Wall St. Rank hold TEVA as of Q1 2021.

Perkins Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Perkins Capital Management sold 20,000 Teva Pharmaceuticals shares in Q1 2021, an estimated $193K.
Perkins Capital Management first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 8 quarters.
Perkins Capital Management's Teva Pharmaceuticals position peaked at $330K in Q1 2015.
451 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2021.

Based on Perkins Capital Management's 13F filing for Q1 2021, filed 28 Apr 2021.